Activation of connective tissue cells in vital pericardium relevance to the behavior of vital autologous pericardial implants in cardiovascular surgeries by Marchion, Douglas C.
University of Montana 
ScholarWorks at University of Montana 
Graduate Student Theses, Dissertations, & 
Professional Papers Graduate School 
2001 
Activation of connective tissue cells in vital pericardium relevance 
to the behavior of vital autologous pericardial implants in 
cardiovascular surgeries 
Douglas C. Marchion 
The University of Montana 
Follow this and additional works at: https://scholarworks.umt.edu/etd 
Let us know how access to this document benefits you. 
Recommended Citation 
Marchion, Douglas C., "Activation of connective tissue cells in vital pericardium relevance to the behavior 
of vital autologous pericardial implants in cardiovascular surgeries" (2001). Graduate Student Theses, 
Dissertations, & Professional Papers. 9409. 
https://scholarworks.umt.edu/etd/9409 
This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an 
authorized administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
INFORMATION TO USERS
This manuscript has been reproduced from the microfilm master. UMI films 
the text directly from the original or copy submitted. Thus, some thesis and 
dissertation copies are in typewriter face, while others may be from any type of 
computer printer.
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality illustrations 
and photographs, print bleedthrough, substandard margins, and improper 
alignment can adversely affect reproduction.
In the unlikely event that the author did not send UMI a complete manuscript 
and there are missing pages, these will be noted. Also, if unauthorized 
copyright material had to be removed, a note will indicate the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand comer and continuing 
from left to right in equal sections with small overlaps.
Photographs included in the original manuscript have been reproduced 
xerographicaliy in this copy. Higher quality 6” x 9” black and white 
photographic prints are available for any photographs or illustrations appearing 
in this copy for an additional charge. Contact UMI directly to order.
ProQuest Information and Learning 
300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 
800-521-0600
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
NOTE TO USERS
This reproduction is the best copy available.
UMI’
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Maureen and Mike 
MANSFIELD LIBRARY
The University o f
________________Montana
Permission is granted by the author to reproduce this material in its entirety, 
provided that this material is used for scholarly purposes and is properly cited in 
published works and reports.
**Please check "Yes" or "No" and provide signature**
Yes, I grant permission 2^  ̂
No, I do not grant permission ___________
Author's Signature:
Date:
Any copying for commercial purposes or financial gain may be undertaken only with 
the author's explicit consent.
M S T hesisvM ansfie ld  U b ra rv  P e rm is s io n
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Activation of Connective Tissue Ceils in Vital Pericardium, Relevance 
to the Behavior of Vital Autologous Pericardial Implants in 
Cardiovascular Surgeries
Douglas C. Marchion 
M.S., University of Montana, Missoula, MT 2001 
Presented in partial Fulfillment of the Requirements 
for the degree of 
Doctor of Philosophy 




Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
I Ik II fc l  I _ , OAAAftOA
u i v n  i n u i i i u G i . o u z z u o v
___ ®
UMI
UMI Microform 3022080 
Copyright 2001 by Be!! & Howe!! Information and Learning Company. 
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17. United States Code,
Bell & Howell Information and Learning Company 
300 North Zeeb Road 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Marchion, Douglas C., PhD, September 2001
Activation of Connective Tissue Cells in Vital Pericardium, Relevance 
to the Behavior of Vital Autologous Pericardial Implants in
Cardiovascular Surgeries
Chairperson: Ralph C. Judd - i f
The use of vital autologous pericardium as a cardiovascular repair biomaterial has 
produced mixed results. Autologous pericardium was found to behave favorably as a 
patch for left ventricle repair and atrial septal defect closure and a s a conduit for 
pulmonary artery and right ventricular outflow-tract reconstruction. In contrast, fresh 
autologous pericardium became fibrotic when used for mitral valve chordae and leaflet 
repair. Our laboratory investigated healing reactions of vital autologous pericardium 
implanted as a flap in the descending aorta of sheep (a model that simulated a heart 
valve leaflet, Cheung et al., 1999). In this in vivo model the pericardium became 
fibrotic and was characterized by cellular accumulation and tissue retraction.
Histological analysis of recovered implants indicated that activation of cells 
endogenous to the pericardium contributed to the detrimental healing outcome.
Here we report an in vitro model of pericardial tissue healing using living pericardium. 
In this in vitro model, pericardial tissue contracted and the cells in situ expressed the 
proliferative marker PCNA and procollagen. These physical and cellular changes of 
cultured pericardium were stimulated Toy blood serum in a dose dependent manner and 
could be modulated by chemical inhibition of protein synthesis and protein function. In 
these studies, serum-stimulated pericardial tissue contraction was dependent upon the 
synthesis and deposition of Type I collagen. The mechanism of tissue contraction 
through the deposition of collagen is unknown. In addition, serum-stimulated cellular 
proliferation was independent of both tissue contraction and coiiagen synthesis. These 
data suggest that fibrosis of vital autologous pericardium in vivo may occur in response to 
the activation of cells in situ to the implant. One mechanism of cellular activation was 
through the exposure to blood serum. Data acquired from this in vitro study indicated 
that the microenvironment associated with cells and tissues is unique to those tissues and 
changes in tissue microenvironment may result in cellular activation and possible 
detrimental healing reactions.
a
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INTRODUCTION
Pericardium is a fibro-serous membrane that surrounds the heart functioning to 
reduce friction as the heart beats. It is composed of two distinct surfaces, the fibrous 
layer, and a serous layer. The serous layer faces the heart and is covered by 
mesothelial cells; a type of endothelial cell, while the fibrous layer faces away from the 
heart and is covered by loose tissue and fat. When pericardium is used in 
cardiovascular surgeries, the loose tissue, fat, and mesothelium are removed.
Autologous pericardium has many advantages as a cardiovascular repair 
material. It is non-immunogenic, free of donor-derived pathogens, shows excellent 
hemostatic qualities, and is easy to access [1,2]. However, autologous pericardium was 
found to behave differently depending upon its usage. When used as a patch, vital 
autologous pericardium was found to behave favorably for left ventricle repair [3,4] 
and atrial septal defect closure [2]. When used as a conduit, vital autologous 
pericardium functioned well for pulmonary artery [5] and right ventricular outflow 
tract reconstruction [6,7].
In contrast, vital autologous pericardium became fibrotic when used for mitral 
valve chordae and leaflet repair [8]. Aneurysmal changes were observed following 
patch reconstruction of large ventricular defects, or right ventricular outflow tract 
repair with distal pulmonary hypertension [5,9]. To avoid these changes, some 
authors have suggested fixation of the pericardium with glutaraldehyde [10].
Understanding the behavioral variability of vital pericardial implants would 
allow for the development of strategies to control the outcome of the implant. For this 
reason, Cheung el al. implanted vital autologous pericardium as a patch, conduit, and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
flap in the descending aorta of sheep [11]. The implants were placed in the same 
location and differed only by configuration and therefore hemodynamic stresses.
Thirty days after implantation, the patch and conduit showed organized layers of ct- 
smooth muscle cell actin (ec-actin)-expressing cells covered by a surface layer of cells 
expressing von Willebrand Factor (vWF). In contrast, a-actin-expressing cells in the 
flap were randomly oriented. The flap was retracted, fibrotic, and never acquired a 
vWF-expressing surface layer of cells.
To determine if vital cells of the pericardium contributed to the fibrotic 
reactions of the flap, Cheung et al. killed the intrinsic pericardial cell population by 
washing the tissue with 50% ethanol for 5min [11]. The ethanol-treated autologous 
pericardium was implanted as a patch, conduit, and flap in the descending aorta of 
sheep.
Thirty days after implantation, the ethanol-treated pericardial flap was found to 
be repopulated by host cells and had a continuous surface layer of vWF-expressing 
cells, indicative of an endothelium. There were no signs of fibrosis. The reasons for 
the observed differences are unknown but are thought to involve normal wound healing 
responses.
Wound Healing
The process of wound healing has been extensively characterized in the skin. 
Cutaneous wound healing can be described in three phases; inflammation, granulation 
tissue formation, and extracellular matrix remodeling [12,13]. Inflammation is 
triggered by injury and is designed to restore structure and function to the tissue [12]
2
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while preventing systemic infection [13]. Damage to blood vessels results in 
denudation of the endothelium, exposing collagen types IV and V on the 
subendothelium [12]. Exposure of collagen promotes binding and subsequent 
activation of platelets. Activated platelets degranulate and interact with fibrinogen, 
fibronectin, vWF, and thrombospondin to prevent blood loss by forming a platelet plug 
[14]. Platelet degranulation results in the release of factors including transforming 
growth factor a  (TGFa) and j3]5 platelet derived growth factor (PDGF), epidermal 
growth factor (EGF), insulin-like growth factor (IGF), serotonin, fibronectin, 
adenosine diphosphate, thromboxane, platelet activating factor (PAF), platelet factor-3 
and platelet factor-4 into the local environment [12]. Platelet factor-3 interacts with 
blood coagulation proteins resulting in the formation of a fibrin matrix. The fibrin 
matrix strengthens the platelet plug and provides binding sites for cellular infiltration 
[14].
The first cell type to migrate into the wound site is the neutrophil [12]. 
Neutrophils clean the wound, removing invading microorganisms by phagocytosis, and 
degrading damaged tissue by the release of elastase and collagenase [12]. Subsequent to 
the neutrophil, the macrophage becomes the dominant cell type at the wound site in 
response mainly to TGFf3„ but also bacterial products and complement components [12], 
Macrophages remain at the wound site for several weeks and mediate wound repair by 
cytokine secretion [12].
The second phase of wound healing is the granulation tissue formation. The 
formation of granulation tissue is coordinated by macrophage which recruit fibroblasts
3
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and other cell types to the wound site. Fibroblasts are attracted and activated by PDGF 
and TGFp,. Activated fibroblasts migrate to the wound and secrete FDGF and TGFp, 
with autocrine activity [13]. TGFp, induces fibroblast synthesis of collagen Types I and
III. The fibroblasts then acquire a smooth muscle cell phenotype characterized by the 
synthesis of a-actin, and participate in wound contraction [13].
After contraction, macrophage and fibroblasts release the growth factors TGFa, 
TGFP„ EGF, and VEGF that activate and recruit endothelial cells [13]. The endothelial 
cells form capillaries through the fibrin matrix. Pericytes migrate along the capillary 
tubes and encircle them. Together, endothelial cells and pericytes deposit collagen type 
IV to form a basal lamina around the vessel [13].
The final phase of wound healing is extracellular matrix remodeling [13]. During 
this phase, the total cell number continually decreases while collagen type III is degraded 
and replaced by collagen type I [13]. TGFp, plays a major role in this phase of wound 
healing by having both positive and negative control of collagen synthesis [12]. TGFp, 
and PDGF induce the synthesis of procollagenase by fibroblasts [12]. Procollagenase is 
cleaved to collagenase by metallo-proenzymes and inhibited by tissue inhibitor of 
metallo-proteinases (TIMP) [12]. In contrast, TGFp, has been shown to block the 
production of procollagenase induced by other growth factors and induce the production 
of TIMP [12]. In concert with PDGF, TGFp, stimulates fibroblast production of 
glycosaminoglycans and proteoglycans and induces the synthesis of collagen and 
fibronectin [13]. TGFp, modulates a decrease in cell density by inhibiting endothelial cell
4
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proliferation. In addition, TGFp, blocks the effects of PDGF on fibroblasts and the 
effects of bFGF on endothelial cells [13].
In terms of arterial wound healing, where pericardium is used to reconstruct heart 
valve leaflets, or patch cardiac defects, the cell types of concern are endothelial cells, 
smooth muscle cells, and fibroblasts.
Endothelial cells
Endothelial cells form the friction reducing lining of the heart, blood vessels, and 
lymphatic vessels [15-17]. The endothelium maintains blood flow and controls the 
trafficking of circulating cells out of the vascular system into the surrounding tissue [18]. 
The endothelium is involved in numerous metabolic functions such as angiogenesis [19], 
[20], coagulation [21], thrombolysis [22], basement membrane synthesis [22,23], 
production of growth factors [21,24], and regulation of vascular tone [25-27].
The endothelium has a critical function in the maintenance of the vascular 
system. By secretion of soluble factors, such as nitric oxide and heparin-binding 
epidermal growth factor-like growth factor, the endothelium is thought to regulate the 
function of smooth muscle cells (SMC) in the underlying media [25].
Arterial wound healing models suggest loss or disfunction of the endothelium 
may result in activation of SMC [28]. Several laboratories have noted the importance 
of endothelial cell-SMC interaction in relation to arterial wound healing. This research 
indicated that hyperplasia of SMC in the intima occurred specifically in areas where 
the endothelium was absent. In other areas, where a rapid regeneration of the
5
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endothelium occurred, SMC migration and proliferation in the intima was not observed
n o . - inj. j .
Smooth Muscle cells
Smooth muscle cells are specialized cells of the arterial media that regulate 
blood pressure and blood flow [32]. In the developing organism, SMC are in a 
synthetic state characterized by increased proliferation, large endoplasmic reticulum, 
large golgi complex, p-actin synthesis, and secretion of extracellualr matrix 
components [32]. In the fully developed organism, SMC differentiate from a synthetic 
to a contractile activation state. This differentiation is characterized by a switch from 
P-actin production to a-actin production [33], a size reduction of the endoplasmic 
reticulum and golgi complex, increased myosin and myofilament synthesis, and a 
slower growth rate [32]. It is not known what induces SMC to differentiate into a 
contractile state of activation. However, it is known that this differentiation is not 
terminal. In certain pathological situations SMC are stimulated to revert back to a 
synthetic state. Reversion of SMC activation state has been documented in 
pathological situations involving atherosclerosis [34, 35], restenosis after coronary 
angioplasty [36], restenosis after coronary and peripheral artery bypass using 
autologous saphenous vein grafts [37-39], angiogenesis [25], and experimental wound 
healing [28].
Several factors may influence SMC transition to a synthetic state of activation. 
Nitric oxide (NO) produced by endothelial cells was shown to inhibit SMC growth 
[40], whereas soluble factors released from platelet a-granules were shown to have a
6
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stimulatory effect on SMC mitogenesis [41]. Among the SMC stimulatory factors
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IGF-1 [46]. Taken together, reduction of local NO and stimulation of platelet 
aggregation and degranulation due to the loss of endothelium may be responsible for 
SMC reversion to a synthetic state. Reversion to a synthetic state would allow for 
SMC migration into the intima and SMC proliferation resulting in many disease states 
of the cardiovascular system.
Fibroblasts / Myofibroblasts
Fibroblasts are the dominant cell type of arterial adventitia and connective 
tissues. Towards the conclusion of the inflammation phase during cutaneous wound 
healing, factors released from platelets and macrophage recruit cellular infiltrates to the 
wound site [13,47]. Of these cellular infiltrates, fibroblasts are attributed with the 
majority of new matrix deposition [13]. Fibroblasts in the wound secrete collagen and 
differentiate into myofibroblasts [48,49].
The myofibroblast is a specialized phenotype of fibroblasts that functions in 
wound contraction [13, 50]. The myofibroblast has features common to both 
fibroblasts and smooth muscle cells such as the synthesis of a-actin, desmin, and 
vimentin [51]. Although the differentiation between myofibroblasts and smooth 
muscle cells is at best subtle, myofibroblasts may be distinguished from other cell 
types by ultrastructure. Schurch et al., 1998, define the myofibroblast as having 
isolated bundles of a-actin stress fibers, a feature not distinguishable in smooth muscle
7
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cells [52]. In addition, the myofibroblast may be identified by distinct cell to stroma 
attachment sites, and intracellular gap junctions [52].
In vitro experimentation has suggested that TGFp,-stimulation is responsible 
for inducing the phenotypic change of fibroblasts into myofibroblasts. lessen and 
Petersen, 1993, reported that a-actin-negative breast fibroblasts became a-actin 
positive upon addition of TGFp, in culture [53].
In terms of wound healing, the myofibroblast participates in wound contraction, 
collagen deposition, and scar formation [48]. Although the myofibroblast has a 
valuable function in wound healing, it has been associated with various pathologies 
that result in deformation of tissues [50]. These pathologies include idiopathic 
pulmonary fibrosis [54], fibrosis of the breast after radiation [55], renal fibrosis [56], 
liver fibrosis [57], etc. Studies of experimental wounds have shown that scarring may 
be reduced by addition of TGF-P3 [58], which has been shown to prevent fibroblast 
transition into myofibroblasts [59]. In addition, experimental tubulointerstitial fibrosis 
was prevented by the addition of the angiotensin converting enzyme inhibitor enalapril 
[60]. Enalapril was shown to prevent fibrosis by decreasing the interstitial 
accumulation of myofibroblasts. This suggests that pathologies involving fibrosis may 
be a direct result of myofibroblast persistence. In fact, it has been documented that 
myofibroblasts are induced into apoptosis soon after wound contraction [61]. The 
apoptotic signal has not been identified, but may involve re-epithelialization of the 
wound [62,63].
8
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Cardiovascular Wound Healing
Whereas wound healing has been studied in the skin, wound healing is not well 
documented in the cardiovascular system. Our laboratory investigated cardiovascular 
wound healing as it related to vital autologous pericardial transplants. Although the 
clinical use of vital autologous pericardium has been extensively reported, the healing 
variability associated with these implants has not been studied. We explored the 
healing behavior of pericardial implants using the juvenile sheep model. Vital and 
ethanol-treated autologous pericardium was implanted as a patch, conduit, and flap in 
the descending aorta of Targhee sheep [11]. Thirty days after implantation, there was 
an orderly invasion and subsequent repopulation of all ethanol-treated implants by cells 
from the surrounding host tissue. The endothelium was restored and the implants 
essentially became an extension of the native host tissue. In short, the healing process 
appeared controlled and was completed by the conclusion of the experimental time 
period of 30 days.
In contrast, much more activity was seen during the healing process of vital 
autologous transplants. Significantly more clot deposition, fibrin accumulation, and 
cellular disorganization was observed with the vital patch and conduit than the ethanol- 
treated counterparts. However, these tissues eventually regained an endothelium and 
were also incorporated into the surrounding tissue. Successful healing was not 
observed when vital autologous pericardium was implanted directly in the blood 
stream as an intraluminal flap. With this implant, continual clot deposition was seen 
through the experimental time period. This deposition resulted in a build-up of 
granulation tissue with cellular invasion, matrix synthesis, and capillary formation.
9
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Proliferating cells were concentrated at the interface between the granulation tissue and
newly deposited clot, which suggested a self-renewing cycle of tissue accumulation.
The tissue of the original pericardial implant, which showed signs of retraction by day
15, was thickened by day 30 from collagen synthesis by in situ cells. In fact, by day
30, some sections of the original implant were indistinguishable from the surrounding
granulation tissue. By conclusion of the experimental time period, the vital pericardial
flap was a mass of fibrotic tissue that no longer resembled the original implant and
never regained an endothelium. In this respect, the vital flap resembled a chronic
wound where the healing process was incomplete resulting in the loss of functional
integrity of the implant.
It is not known why the vital patch and conduit were accepted into the
surrounding tissue while the vital flap was not. Furthermore, all ethanol-treated implants
were incorporated regardless of the implant configuration. Taken together, these data
suggested that cellular activation contributed to the detrimental healing outcomes of the
vital pericardial flap. However, the question remains as to which cells were activated and
what was the activation signal. The above in vivo experiment confirmed that cells in situ
to the implants were required for the development of fibrosis. However, these cells may
interact and therefore be activated by cells from the host aortic wall and blood stream as
well as soluble factors within the blood.
The First Hypothesis of this study is:
Fibrosis of vital autologous pericardial transplants is promoted by activation of in 
situ cells.
10
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proliferate, and synthesize new matrix resulting in tissue contraction and 
thickening.
The Third Hypothesis is:
Tissue contraction, cellular proliferation, and matrix synthesis are independent 
events.
To test these hypotheses, the following Specific Aims were investigated:
1. An in vitro model of pericardial tissue contraction that simulated the healing 
responses associated with the vital fibrotic pericardial flap was developed. These 
healing responses included tissue contraction, cellular proliferation, and collagen 
deposition.
2. Cells in situ to cultured pericardium were activated with blood serum and the 
ability of activated cells to contract pericardial tissue, proliferate, and synthesize 
collagen was investigated. The mechanism of serum-stimulated cellular 
activation was evaluated using chemical inhibition of protein synthesis and 
function, and cellular proliferation.
3. The stimulatory component of serum capable of inducing cultured pericardial
tissue contraction was characterized in terms of molecular weight range, heat 
sensitivity and protease sensitivity.
4. The mechanism of serum-stimulated tissue contraction was investigated using
time related SDS-PAGE protein profiles of cultured pericardial tissues stimulated 
with serum with and without the presence of inhibitors of protein synthesis.
5. The relationship between serum-stimulated tissue contraction and cellular
proliferation, collagen synthesis and cellular proliferation, and tissue contraction 
and collagen synthesis using chemical inhibition of protein synthesis and 
function, and cellular proliferation.
I. In Vitro Modelling of Wound Healing
This study focuses on understanding the activation of cells within cultured
pericardial tissue to gain insight into the development of fibrosis observed in the vital
autologous pericardial flap. Although in vivo models of fibrosis would best represent
11
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actual clinical situations, these studies are expensive, time consuming, and do not allow 
for the isolation of variables, which may be responsible for the observed results. The 
approach used in this investigation was the development of an in vitro model of fibrosis 
and tissue contraction that simulated healing outcomes associated with the fibrotic 
pericardial flap in vivo.
Whereas the majority of in vitro models are composed of a homogenous matrix 
seeded with a particular cell type, this model incorporated living tissue complete with 
native cell types and extracellular matrix. Recently, Kratz et al, 1998, reported two in 
vitro wound healing models using viable human skin explants [64]. These models 
allowed for the interaction of mixed cell types native to the tissue and the cells 
maintained natural morphology and proliferative activity after 14 days of incubation. 
Furthermore, each of these models showed distinctive healing responses characteristic of 
incision and bum wounds that were similar to healing responses observed in clinical 
cases. Here we offer a living tissue model of pericardial wound healing. The pericardial 
tissue used in this model was processed analogously to the pericardium used in vivo, with 
the mesothelium being removed prior to the experiment. This in vitro model allowed 
components of the cardiovascular system to be systematically screened for the ability to 
activate cells within vital pericardial tissue sections to contract the tissue, proliferate, and 
deposit de novo collagen.
In order to adequately screen cardiovascular factors for the ability to activate 
cells within cultured pericardium, a comparison needed to be made between stimulated 
tissue and native tissue. Pericardium was harvested from normal sheep and 
immediately placed in fixative. Although this harvesting was designed to minimize
12
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mechanical stimulation through handling, significant differences, both macroscopically 
and histologically, were observed between pericardial sections from different sheep as 
well as pericardial sections from the same sheep. Macroscopically, these differences 
were in tissue thickness and loose tissue adhesions. Microscopically, these differences 
were in cellular density and proliferative activity. For this reason, harvested 
pericardial tissue sections were cultured for 48hr in serum-deprived conditions.
Serum deprivation was used to induce pericardial cells into a quiescent state [65] 
allowing comparisons to be made between stimulated and unstimulated samples. 
Furthermore, the proliferative index used in this study was proliferating cell nuclear 
antigen (PCNA). PCNA has a half- life of approximately 20hr [66]. Therefore, 48hr 
serum deprivation was used to prevent PCNA staining of cell just leaving the cell 
cycle.
In this in vitro model, cardiovascular factors, such as serum, were screened for 
the ability to activate cells within serum-starved pericardial tissue sections. Activated 
cells were evaluated for the ability to contract the tissue, proliferate, and synthesize 
Type I collagen as observed during the fibrotic development of the in vivo vital 
autologous pericardial flap.
Materials and Methods 
Harvesting o f Pericardial Tissue
Parietal pericardium was harvested from sheep and the loose tissue, adhesions, 
and the mesothelium were removed using sterile gauze. The tissue was dissected into 
approximately 1cm2 sections and serum starved by incubation with Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco BFX, Gaithersburg, MD) containing 0.5%
13
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fetal bovine serum (FBS, HyClone, Logan, UT) for 48hr prior to experimentation. 
Tissues were then incubated with DMEM containing 20% FBS (DMEM/20% FBS) for 
up to 30 days. Control tissues included pericardium killed by freezing at -20°C for 1 
week prior to use and pericardium killed by a 5min wash in 50% ethanol shown 
previously to kill all cells within the tissue [11].
Histology
Specimens were fixed in Histo-Choice (Amresco Inc., Solon, OH) for a 
minimum of 12hr. The sections were dehydrated and embedded in PoiyFin 
(Polysciences, Inc.) wax for sectioning. Wax blocks were sectioned at 5pm and 
collected on poly-L-lysine coated slides. Histological stains included hematoxylin and 
eosin (H&E) for visualization of cell nuclei and tissue matrices respectively, as well as 
Masson's Trichrome for collagen density.
Immunohistochemistry
Tissue samples were analyzed by immunohistology for the synthesis of 
proliferating cell nuclear antigen (PCNA) (Sigma Chemical Co., St. Louis, MO). 
Sections were deparaffinized and the tissue was unmasked by lOmin microwaving on 
high power in 0.01M citrate. Unmasked tissues were treated with 3% H202 for 5min to 
remove endogenous peroxidases. The sections were blocked with 0.05% Tween-20 
(Sigma Chemical Co., St. Louis, MO) in phosphate-buffered saline (PBS-T) with 10% 
normal sheep serum (NSS) for 30min and incubated with an appropriate concentration 
of primary antibody in PBS-T, 10% NSS for 30min. Sections were rinsed with PBS-T 
and incubated with the LSAB-2 strepavidin-biotin amplification kit (DAKO,
14
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Carpinteria, CA). All incubations were performed in a moist chamber at room 
temperature. Sections were rinsed with PBS-T and lOOpl of diaminobenzine (DAB) 
substrate (Sigma Fast DAB, Sigma Chemical Co., St. Louis, MO) added to each 
section for development. For some tissues, development was performed using the 
ImmunoPure metal enhanced DAB substrate kit (Pierce, Rockford, IL). The 
development was stopped with water and the slides counter stained with H&E. 
Negative controls included using an irrelevant primary antibody or replacing the 
secondary antibody with PBS-T. A positive control, such as a tissue known to express 
the marker in question, was used for every immunohistochemical stain.
Results
Pericardial tissues incubated in 0.5% FBS for 48hr showed greater than 95% 
cell viability by Trypan Blue staining. The cells in situ to cultured pericardium became 
activated after incubation in DMEM, 20%. This activation resulted in cell-mediated 
tissue contraction (Figure 1), cellular synthesis of PCNA (Figure 2), and cellular 
collagen synthesis and subsequent deposition (Figure 3). Cellular activation was the 
result of serum stimulation since serum-free DMEM did not induce physical changes 
to cultured pericardium (not shown). Furthermore, these physical and cellular changes 
observed during the culture of living pericardium were absent in freeze-killed and 
ethanol-treated tissues (Figure 1).
Conclusions
In vitro models are necessary for the thorough investigation of complex 
biological processes because they allow selective manipulation of the testing
15
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 1. Comparison of vital and killed pericardial tissue sections within the in vitro 
model of retraction and fibrosis. Vital tissue sections incubated in the presence of fetal 
bovine serum resulted in the activation of cells within the pericardium and subsequent 
contraction of the tissue (yellow arrow). Tissues killed by freeze-thaw or by a 5niin 
wash in 50% ethanol did not contract (blue arrow).
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Figure 2. Immunohistological detection of PCNA. Antibody recognition of 
proliferating cell nuclear antigen was detected by DAB development resulting in a 
brown precipitate (yellow arrows) and indicates dividing cells. Tissues were counter 
stained with Hematoxylin, which stains nuclei blue, and Eosin, which stains collagen 
pink. The pericardial tissue was incubated in DMEM medium containing 20% fetal 
bovine serum. 400x
18
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Figure 3. Collagen deposition by cells within pericardial tissue. Masson’s Trichrome 
collagen density stain showing new' collagen deposition (light blue, yellow' arrow') in 
the folds of the original pericardial tissue (dark blue). Collagen production was 
observed 15 days after incubation in DMEM containing 10% fetal bovine serum. lOOx
20
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environment. The popular model for studying tissue retraction and its relation to 
wound healing is fibroblast populated type I collagen gels (FPCG). Bell et al., 1979, 
first developed FPCG to study fibroblast function [67]. Since then, FPCG were used 
to explore fibroblast response to chemical mediators [68- 72] and were modified to 
accommodate other cell types such as chondrocytes [73], keratocytes [70] H29 colon 
carcinoma cells [74], etc.
Through the use of FPCGs, three main schools of thought have arisen regarding 
the contraction of wounds. The first, as occurs in skin wound healing, involves the 
transformation of fibroblasts into myofibroblasts [12,13]. In this theory, fibroblasts 
acquire a contractile phenotype expressing a  smooth muscle cell actin [72, 75, 76] and 
compress the collagen filaments of the gel. The other theories suggest that locomotion 
and intracellular tension forces, which are interrelated in the aspect that both are 
modulated by adhesion molecules and cytoskeletal actin reorganization, are 
responsible for wound contraction. Nunohiro et al., 1999, showed angiotensin II or 
osteopontin-induced gel contraction was blocked by antibodies specific for p3 integrins 
and RGD peptide [69]. Other researchers showed a 2 P , integrins [70,77] may mediate 
collagen gel contraction suggesting more than one signalling pathway might be 
involved. Furthermore, Tomasek et al., 1992, reported two phases of gel contraction, 
rapid and slow, and that an organized cytoskeleton was required for contraction to 
occur [78], a process later shown to result in an increase in f-actin production [68].
Lee et al., 1996, also reported the requirement of an organized cytoskeleton, showing
11
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the addition of Cytochalasin, an inhibitor of f-actin polymerization, to the culture 
medium suppressed fibroblast-mediated gel contraction [79].
In addition to exploring the mechanism of contraction, researchers have 
investigated the ability of soluble blood factors to stimulate FPCG contraction. Since 
the development of the collagen gel model, serum has been known to induce collagen 
gel contraction by fibroblasts [80], and that the rate of gel contraction was proportional 
to serum concentration [73]. Recently, researchers have been examining the 
components of serum that may modulate gel contraction by fibroblasts. Growth 
factors such as TGF-P, [79], PDGF [73, 79], and IGF-1 [71, 79, 81] were shown to 
augment FPCG contraction whereas bFGF [82] was shown to suppress contraction. 
Furthermore, compounds like glucocorticoids [68,83] and indomethacin [68] also 
modulate gel contraction by regulating fibroblast synthesis of prostaglandin E2 (PGE2).
However, FPCG may be overly simplistic to accurately reflect cardiovascular 
wound healing. First, these models do not allow for the multiple events that occur 
during natural wound healing with interactions between different cell types, proteases, 
and chemical messengers [80]. Secondly, it is well known that the extracellular matrix 
has significant influences on cell morphology and function [79, 80,84, 85] suggesting 
cells in vitro do not always reflect cells in vivo. Finally, FPCGs were developed to 
model wound healing as it relates to skin wounds where there is a low density of cells 
and a loosely organized matrix.
In our in vitro model of pericardial tissue contraction and fibrosis, living tissue 
was used to simulate healing outcomes associated with autologous pericardial implants
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in vivo. This tissue was composed of the native cells and complex extracellular matrix 
with the exception of the mesothelium. Using this model, pericardial tissue was serum 
starved to induce internal cells into a quiescent state and subsequently activated using 
stimulants. Activation of the ceils in situ to pericardial tissue resuited in tissue 
responses similar to those observed during the fibrotic healing reactions of the in vivo 
vital autologous pericardial flap implant including tissue contraction, cellular 
proliferation, and collagen deposition.
II. Activation of Cells within Cultured Pericardium
The fibrotic reactions of the vital autologous pericardial flap included tissue 
retraction, cellular accumulation, and collagen deposition. Analogous reactions were 
observed in living pericardial tissue sections cultured within an in vitro model of tissue 
contraction and fibrosis. Within this model, pericardial tissue sections contracted, 
evidenced by tissue curling, and the cells in situ expressed the proliferative marker, 
PCNA, and synthesized collagen. Common to both the in vivo and in vitro models 
was the presence of serum. For this reason, in this section, FBS was analyzed for the 
ability to activate cells within cultured pericardial tissue. Dose and time dependency 
experiments were used to relate stimulants and cellular activation using tissue 
contraction, PCNA production, and collagen synthesis as activation indicators. In 
addition, the stimulatory component within FBS was categorized by molecular weight 
range as well as heat and protease sensitivity using tissue contraction as an indicator of 
cellular activation. The mechanism of serum-stimulated tissue contraction, cellular 
proliferation and collagen synthesis was evaluated using chemical inhibitors of protein 
synthesis and protein function, and SDS-PAGE generated protein profiles.
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Materials and Methods
L i i i r r tu iu i iL / r i  u j  vmmicui cr itur u i u n i
Pericardial tissue was harvested and processed as described previously. Tissue 
sections were transferred to Costar 24-well tissue culture plates (Coming Inc., Coming, 
NY) and incubated as free-floating sections with DMEM (1ml) containing 0.5%, 5%, 
10%, 20%, or 50% FBS for 7 days with the media being replaced every other day. 
Media were purchased at IX concentration and mixed with the appropriate volume of 
FBS to achieve the desired percentage of FBS with the exception of 50% FBS which 
was mixed 1:1 with 2X DMEM to insure an appropriate buffering capacity of the 
medium. Controls included ethanol-treated pericardial tissues.
The degree of tissue contraction was determined using circular pericardial disks 
(lcm in diameter) generated using a standardized punch. Disks were incubated in 
DMEM/20% FBS for 7 days and fixed in Histo-Choice (Amresco Inc., Solon, OH). 
Pericardial disks immediately fixed in Histo-Choice were used as the control. 
Contracted and control samples were traced on transparency film and the weights of 
cut out tracings were compared to determine the decrease in 2 dimensional surface 
area. The degree of contraction was thus defined as the average percent decrease in 
weight of cut out tracings of contracted samples when compared to control tissues.
l f i r i i t S M tu r i  O J p B t  t C u t u l u i  i t o S w c ic/m# u ^ t n / e t
Various inhibitors were added to DMEM containing 20% FBS (DMEM/20% 
FBS) for up to 30 days to determine the ability of these compounds to prevent 
pericardial tissue contraction. Inhibitors included Mitomycin C and Actinomycin D
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(Ipg/ml, Sigma Chemical Co., St. Louis, MO), inhibitors of nucleic acid synthesis;
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arabinofuranoside (AraC, 1 (ag/ml, Sigma Chemical Co., St. Louis, MO), inhibitors of 
DNA synthesis: Cytochaiasin B and Cytochaiasin D (1 lag/ml, Sigma Chemical Co., St. 
Louis, MO), inhibitors of contractile actin filament formation; Colchicine and 
Nocozadole (0.0078pg/ml, Sigma Chemical Co., St. Louis, MO), microtubule 
depolymerizers; Cycloheximide (lpg/ml, Sigma Chemical Co., St. Louis, MO) an 
inhibitor of protein synthesis; and Halofuginone (lOOng/ml, Collgard 
Biopharmaceuticals, LTD, Petach Tikva, Israel), an inhibitor of collagen type I 
synthesis. Inhibitors were used at the maximum concentration that showed no 
cytotoxicity of fibroblast monolayers. Pericardial tissue sections were incubated as 
free-floating sections in Costar 24-wells tissue culture plates with DMEM/20% FBS 
containing the above chemical inhibitors. The media (1ml) were replaced every other 
day and the sections were maintained at 37°C with 5% C 02. Controls included tissues 
incubated in DMEM/20% FBS without inhibitors. Inhibitor toxicity was evaluated 
using fibroblast monolayers isolated from vital pericardium and was defined as the 
concentration of inhibitor that induced rounding and loss of adherence of fibroblasts 
cultured in monolayers.
Characterization o f the Stimulatory Component o f Serum
In order to determine characteristics associated with the stimulatory component 
within serum, FBS was fractionated using Centricon centrifugal filters (Millipore, 
Bedford, MA). Molecular weight fractions, > lOOkDa, 30-99kDa, and 5-29kDa, were
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obtained by centrifugation for 15min at 4,000 x g (20°C) using a Beckman J2-21 
centrifuge (Beckman instruments Inc., Palo Alio, CA). Concentrated fractions were 
diluted in 10ml PBS resulting in 5x the original concentration in whole serum and 
added to serum-free DMEM media at 20% of the totai volume. Fractions were 
incubated with serum-starved pericardial tissue sections in Costar 24-well tissue 
culture plates for up to 14 days at 37°C with 5% C 02 and compared to those incubated 
in DMEM/20% FBS.
In addition, the stimulatory capacity of FBS was characterized in terms of heat 
and protease stability. Whole serum was heat treated at 56°C and 70°C for 30min and 
enzyme treated with 5units/ml of proteinase K linked to sephadex beads (Sigma 
Chemical Co., St. Louis, MO) for 30min at room temperature. The digested FBS was 
separated from the enzyme using a Beckman J2-21 centrifuge at lOOOxg. Heat-treated 
and protease-digested FBS were added separately to serum-free DMEM for a final 
concentration of 20% total volume. Treated media (1ml) were used to maintain 
pericardial tissues as free-floating sections in Costar 24 well tissue culture plates. 
Tissues were incubated for up to 14 days at 37°C with 5% C 02, with the media being 
replaced every other day.
Protein synthesis
Pericardial tissue sections were evaluated for de novo protein synthesis during 
the process of tissue contraction. The pericardium was processed as described 
previously. Pericardial sections were serum starved for 48hr, transferred to Costar 24- 
well tissue culture plates and incubated with DMEM/20% FBS for up to 12 days at
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37°C with 5% C 02. The media were replaced every other day. Pericardial tissue 
sections were harvested at day 1 ,2 ,3 ,4 ,5 ,7 ,1 0  and 12 and minced in the presence of 
protease inhibitors. Samples were solubilized and separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) [86]. Protein banding patterns were 
visualized by Coomassie Brilliant blue staining. Controls included tissue incubated 
with DMEM/20% FBS containing the protein synthesis inhibitor, Cycloheximide 
(lpg/ml). Samples incubated with Cycloheximide were harvested at day 12. Protein 
banding patterns were compared between samples at different stages of contraction and 
samples treated with Cycloheximide.
Stimulation o f Cellular Proliferation
Pericardial tissue sections were transferred to Costar 24-wells tissue culture 
plates and incubated as free-floating sections with DMEM containing 0.5,5,10,20, or 
50% FBS. Since the DMEM used here was high glucose (300mg/lt), glucose-free 
RPMI 1640 culturing medium (Gibco BRL, Gaithersburg, MD) containing 50% FBS 
was also used to determine if excess energy aided serum in the stimulation of 
pericardial cells. The carbonate level in the medium was adjusted in order to 
compensate for the differing volumes of serum. The medium was changed daily for 4 
days, and the sections were fixed in Histo-Choice, dehydrated, and embedded. 
Immunohistological analysis using an antibody specific to proliferating cell nuclear 
antigen (PCNA) was performed on 5pm sections. Percentage of cells staining positive 
for PCNA was calculated from 4 replicate tissue samples counting 500 cells per 
replicate in random fields[ (cells expressing PCNA / total cells) x 100].
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Inhibition o f Proliferation
The ability of chemical inhibitors to prevent serum stimulated cellular 
proliferation was investigated using isolated pericardial fibroblast monolayers. 
Pericardial fibroblasts were seeded on Costar 96-well tissue culture plates (Costar, 
Coming, NY) at a concentration of 5,000 cells per well and allowed to adhere in 
DMEM containing 0.5% FBS overnight at 37°C, 5% C 02. Mitomycin C, Cytochaiasin 
B, Cytochaiasin D, Aphidicolin, AraC, and Cycloheximide (lpg/ml) as well as 
Nocozadole (0.0078pg/mi) and Haiofuginone (0.lpg/ml), were incubated separately 
with fibroblast monolayers for 4 days at 37°C, 5% C02. The media were replaced 
every other day and cellular proliferation was assayed using Celltiter 96 (Promega, 
Madison, WI) according to the manufacturer’s protocol. Briefly, the tetrazolium 
compound, [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium (MTS, 20pl) was added to each well containing lOOpl 
DMEM/20% FBS and the plate was incubated for up to 4hr at 37°C, 5% C 02. In this 
assay, MTS is metabolized by fibroblasts to the colored end-product formazan and 
secreted into the medium. Formazan concentration in the medium was assayed by 
optical density recorded at 490nm. Controls included fibroblasts (5000 cells/well) 
incubated with DMEM containing 0.5% and 20% FBS. All assays were performed in 
duplicate.
Pericardial tissue sections were evaluated for the cellular synthesis of PCNA in 
the presence of proliferative inhibitors. Tissues were incubated as free-floating 
sections in Costar 24-wells tissue culture plates with DMEM/20% FBS containing
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either, Mitomycin C (lpg/ml), Aphidicolin (lpg/ml) AraC (lpg/ml), Cytochaiasin B, 
Cytochaiasin D (lpg/ml), Nocozadole (Q.0078pg/mi), Cycloheximide (lpg/ml) or 
Halofuginone (0.lpg/ml). Tissues were incubated for 4 days with the medium being 
replaced every other day. The sections were fixed in Histo-Choice, dehydrated, and 
embedded. The synthesis of PCNA was assessed on 5 pm sections as previously 
described. Percentage of cells staining positive for PCNA was calculated from 4 
replicate tissue samples counting 500 cells per replicate in random fields.
Collagen Synthesis
Pericardial tissues were incubated as free-floating sections in Costar 24-wells 
tissue culture plates with DMEM/20% FBS for up to 30 days. The tissues were 
maintained at 37°C with 5% C02 and the medium was replaced every other day. 
Samples were fixed in Histo-Choice at day 2 ,4, 5 ,6 ,10 ,15 ,25 , and 30, embedded in 
wax, and sectioned onto slides. Sections were stained with Masson’s Trichrome for 
collagen density and probed with a monoclonal antibody specific for sheep procollagen 
(SP1.D8, Develpmental Studies Hybridoma Bank, The University of Iowa, Iowa City,
I A). Immunohistochemistry using the monoclonal SP1 .D8 was performed as 
previously described with the exception that the antigen was first unmasked using 4M 
NaCl at 45°C for 40min followed by 0.01M citrate for 7min in a Sunbeam rice steamer 
(Sunbeam Products Inc., Delray Beach, FL).
Inhibition o f Collagen Synthesis
Pericardial tissue sections were incubated as free-floating sections in 
DMEM/20% FBS containing inhibitors of protein synthesis and function.
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Halofuginone (0. lpg/ml), Cytochaiasin B (lpg/ml), Cytochaiasin D (1 jag/ml), 
Aphidicolin (lpg/ml), AraC (lpg/ml), Nocozadole (0.0078pg/ml), and Cycloheximide 
(lpg/ml) were made fresh and replaced every 48hrs. Samples were harvested at day 5, 
10,20, and 30, fixed in Histo-Choice, and embedded. Embedded samples were 
sectioned onto slides and stained with Masson’s Trichrome stain and probed with 
SP1.D8 as previously described.
Results
Tissue Contraction
Pericardial tissue contraction occurred in a dose-dependent manner to the 
percentage of serum with a peak at 20% (Figure 4). All tissues incubated with 20% 
FBS contracted by day 6 while tissues maintained with 10% and 50% FBS had just 
begun to curl. In contrast, tissues incubated with 0.5% FBS did not contract.
Figure 5 shows a comparison of pericardial disks before and after tissue 
contraction. Experimental pericardial disks incubated with DMEM/20% FBS showed 
an average reduction in 2 dimensional surface area of 71% when control tissues were 
normalized to 100% (Figure 6).
Inhibition o f Tissue Contraction
Serum-stimulated tissue contraction was evaluated in the presence of inhibitors 
of DNA synthesis, protein synthesis, and protein function. Tissue contraction was 
evaluated in the presence of Mitomycin C, Actinomycin D, Aphidicolin, AraC, 
Cytochaiasin B, Cytochaiasin D, Colchicine, Nocozadole, Cycloheximide, and 
Halofuginone. Figure 7 compares pericardial tissue contraction in the presence of
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Figure 4. Dose-dependent tissue contraction in response to serum. Pericardial tissues 
(lcm2. n=4) were incubated with DMEM containing 0.5. 5,10.20, or 50% FBS for 7 
days at 37°C, 5% C 02. The tissues contracted in a dose-dependent manner in response 
to serum with a peak at 20% FBS. Tissues incubated with DMEM containing 0.5% 
FBS did not contract.
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Figure 5. Contraction of vital pericardial disks. Tissue disks (1cm in diameter) were 
generated using a standard punch. Contracted disks were incubated with DMEM/20% 
FBS for 0 and 7 days at 37°C, 5% C02. Disks incubated for 0 days did not contract.
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Figure 6. Degree of tissue contraction. Pericardial tissue disks (1cm in diameter, n=8) 
were generated using a standardized punch and incubated in DmEm/20% FBS for 7 
days at 37°C, 5% C 02 until tissue contraction was observed. A reduction in the 2 
dimensional surface area of contracted tissues was determined by tracing the tissue 
perimeter onto transparency film and weighing cut-outs of the tracings. Weighed 
tracings were compared between tissues incubated for 0 days (control, n=4) and those 
incubated for 7 days (n=4). The degree of contraction was thus defined as the average 
decrease in 2 dimensional surface area of contracted tissues with the control tissue 
disks set at 100%. Tissue contraction stimulated by serum resulted in a 71% decrease 
in surface area. Error bars indicate the range of replicate samples.
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Figure 7. Tissue contraction in the presence of inhibitors. Pericardial tissue sections 
(lcm2 n=4) were incubated for 14 days at 37°C5 5% C 02 with DMEM/20% FBS (1ml) 
in the presence of inhibitors. Inhibitors included, Mitomycin C (lpg/ml); an inhibitor 
of nucleic acid synthesis, Cytochaiasin B (lpg/ml); an inhibitor of f-actin 
polymerization, Cycloheximide (lpg/ml); a protein synthesis inhibitor, Aphidicolin 
(lpg/ml); an inhibitor of DNA synthesis, and Colchicine (0.0078pg/ml); an inhibitor 
of tubulin polymerization. Mitomycin C, Cycloheximide, and Colchicine effectively 
prevented serum stimulated tissue contraction whereas Cytochaiasin B and Aphidicolin 
did not. Colchicine was later found to be cytotoxic.
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Tissue Contraction with Inhibitors
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Mitomycin C, Cytochalasin B, Cycloheximide, Aphidicolin, and Colchicine for 14 
days. Mitomycin C, Cycloheximide. and Colchicine effectively inhibited serum- 
induced tissue contraction whereas Cytochalasin B and Aphidicolin delayed, but did 
not prevent tissue contraction. In addition, Actinomycin D but not Cytochalasin D, 
AraC, and Nocozadole that have analogous functions to Cytochalasin B, Aphidicolin, 
and Colchicine respectively, prevented tissue contraction. Furthermore, Halofuginone, 
a Type I collagen synthesis inhibitor prevented tissue contraction out to 30 days 
(Figure 8). Actinomycin D and Colchicine were shown to be toxic causing cell 
rounding and loss of adhesion of fibroblast monolayers. These inhibitors were 
removed from the rest of the study. Control tissues, incubated with DMEM/20% FBS 
without inhibitors, were contracted by day 7.
Characterization o f Serum Stimulation
Figure 9 shows pericardial tissue sections incubated with DMEM/20% FBS and 
those incubated in molecular weight fractions >100kDa, 30-99kDa, and 5-29kDa for 
14 days. Tissue sections incubated with DMEM/20% FBS and those incubated with 
DMEM containing the serum fraction >100kDa were completely contracted by day 7. 
At this time, tissues incubated with DMEM containing the serum fraction 30-99kDa 
had just began to contract, evidenced by curling of the edges of the tissues toward the 
center. These tissues reached maximum contraction by day 10. Tissues incubated with 
DMEM containing the serum fraction 5-29kDa began contracting by day 10. By day 
14, 50% of the tissues incubated with this serum fraction had contracted. Serum 
fractions under 5kDa did not induce tissue contraction (not shown).
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Figure 8. Tissue contraction in the presence of Halofuginone. Pericardial tissue 
sections (1cm2, n=8) were incubated for 30 days at 37°C5 5% C 02 with DMEM/20% 
FBS (1ml) in the presence of the Type I collagen synthesis inhibitor, Halofuginone. 
Halofuginone (lOOng/ml) effectively prevented serum-stimulated tissue contraction out 
to 30 days. Control tissues incubated with DMEM/20% FBS only, contracted within 6 
days.
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Figure 9. Tissue contraction in the presence of fractionated serum. Fetal bovine 
serum was fractionated into molecular weight ranges of >100kDa, 30-99kDa, and 5- 
29kDa and added separately to DMEM at 20% total volume. Pericardial tissue 
sections (1cm2, n=4) were incubated with 1ml DMEM/20% FBS or DMEM containing 
different serum fractions for 14 days at 37°C, 5% C 02. Tissue contraction was 
observed with all serum fractions above 5kDa. Fractions of serum under 5kDa did not 
induce tissue contraction (not shown).
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Figure 10. Tissue contraction in the presence of treated sera. Fetal bovine serum was 
proteinase K-treated or heat-treated at 56°C and 70°C and added separately to DMEM 
at 20% total volume. Pericardial tissues (n=4) were incubated with 1ml DMEM/20% 
FBS, or DMEM containing proteinase K-treated or heat-treated sera for 14 days at 
37°C, 5% C 02. Tissue contraction was observed with all treated sera, but was 
significantly delayed with proteinase K-treated serum.
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The stimulatory component contained within serum was evaluated in terms of 
heat and protease stability. Figure 10 shows pericardial tissue sections incubated with 
DMEM/20% FBS, serum heated to 56°C and 70°C, and serum treated with proteinase 
K for 14 days. Control tissues incubated in DMEM/20% FBS whole serum and tissue 
incubated in DMEM containing heat-treated sera contracted by day 7. In contrast, 
pericardial tissues incubated with proteinase K-treated serum began contracting at day 
9 but were not completely contracted by termination of the experiment.
Protein synthesis
Pericardial tissue sections were evaluated for protein synthesis during the 
process of tissue contraction. SDS-PAGE protein profiles of tissue sections incubated 
with DMEM/20% FBS were compared to sections incubated in the presence of 
Cycloheximide. Figure 11 is a Coomassie Brilliant blue stained 12.5% polyacrylamide 
gel showing a protein band of approximately 60kDa in day 10 samples that was absent 
in day 2 samples and absent in samples incubated in the presence of Cycloheximide. 
Stimulation o f Proliferation
Fetal bovine serum stimulated the proliferation of cells within pericardial tissue 
sections. This stimulation was not the direct result of mechanical stimulation from 
handling since the tissue serum deprived for 48hr prior to use. Serum stimulation 
resulted in the cellular production of PCNA and was visualized by DAB development 
resulting in a brown precipitate (Figure 2). In a preliminary experiment maximal 
proliferation occurred at day 4 in all samples, suggesting an early proliferative
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response to serum stimulation. Due to data acquired from this preliminary study, 
samples in this experiment were harvested at day 4.
The percentage of cells producing PCNA increased in a dose-dependent manner 
relative to the percentage of FBS present in the medium (Figure 12). Percentage of 
cells staining for PCNA increased from 19% to 61% when the FBS was increased from 
0.5% to 50%. Changes in glucose concentration of the medium did not alter cellular 
production of PCNA since glucose free RPMI 1640 medium showed similar results as 
DMEM medium containing the same concentration of FBS.
Inhibition o f Proliferation
The ability of chemical inhibitors to prevent proliferation was evaluated on 
isolated pericardial fibroblast monolayers. Figure 13 shows the recorded optical 
densities relating to the production of formazan through fibroblast metabolism of MTS 
and relates to cell numbers. Figure 13 shows formazan production by fibroblasts 
incubated with DMEM/20% FBS in the presence of Mitomycin C, Cytochalasin B, 
Cytochalasin D, Aphidicolin, AraC, Cycloheximide, Nocozadole and Halofuginone. 
Formazan production in the presence of inhibitors was compared to formazan 
production by fibroblasts incubated with DMEM containing 0.5% and 20% FBS. A 
decrease in MTS metabolism was observed in the presence of all inhibitors when 
compared to cells incubated with DMEM/20% FBS only (red arrow). In fact, 
fibroblasts incubated with DMEM containing 0.5% FBS (OD=1.8) showed greater 
MTS metabolism than those incubated with DMEM/20% FBS in the presence of all 
concentrations of Mitomycin C, Aphidicolin, AraC, and Cycloheximide.
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Figure 11. Separation of pericardial tissues proteins in a 12.5% SDS-PAGE gel 
stained with Coomassie Brilliant blue. Tissues (n=3) were incubated with 
DMEM/20% FBS for 2 and 10 days and DMEM/20% FBS containing 1 ng/ml 
Cycloheximide for 12 days (C12) at 37°C, 5% C 02. Tissues were diced and boiled in 
SDS-PAGE solubilizing solution. Molecular weight markers (MW) were acquired 
from BioRad. A protein band of approximately 60kDa (red arrow) that appeared 
during the process of tissue contraction is shown at day 10. This protein band was 
absent at day 2 and absent in samples treated with Cycloheximide.
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Figure 12. Percent cellular production of proliferating cell nuclear antigen (PCNA).
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serum concentration in DMEM. Pericardial tissues (n=4) were incubated with 1ml 
DMEM containing 0.5. 5.10.20, or 50% serum for 4 days at 37°C, 5% C 02. Tissues 
were embedded in wax and assayed immunohistologically for the production of 
PCNA. Error bars indicate ranges from replicate tissue samples counting 500 cells per 
replicate in random fields. Percent cellular production of PCNA was calculated as 
follows: [(number of cells staining for PCNA / total number of cells counted) x 100].
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Figure 13. MTS metabolism in the presence of inhibitors. Pericardial fibroblast 
metabolism of MTS into the colored end-product formazan was assayed in the 
presence of inhibitors. Fibroblast monolayers (5000 cells/well, n=4) were incubated 
for 4 days at 37°C, 5% C 02 with Ipg/ml of Mitomycin C, Cytochalasin B, 
Cytochalasin D, Aphidicolin, AraC, Cycloheximide, 0.0078p.g/ml Nocozadole, or 
0.1 pg/ml Halofuginone in DMEM/20% FBS and evaluated for the production of 
formazan using Celltiter 96 proliferation kit (Promega). Formazan production is 
directly related to the number of living cells and was evaluated by absorption at 
490nm. Mitomycin C, Aphidicolin, AraC, Cycloheximide, and Halofuginone greately 
reduced MTS metabolism by cultured fibroblasts when compared to control samples 
(red bar), while Cytochalasin B, Cytochalasin D, and Nocozadole did not. Error bars 
indicate the range of data from replicate samples.
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metabolism. Chemical toxicity indicated by cell rounding and loss of adherence was
nnt observed.
Cellular proliferation was also evaluated by cellular PCNA production in the 
presence of chemical inhibitors of DNA synthesis, protein synthesis, and protein 
function. Figure 14 shows percentages of cells staining positive for PCNA in tissues 
incubated with DMEM/20% FBS containing Cycloheximide, Mitomycin C, 
Cytochalasin B, Cytochalasin D, Aphidicolin, AraC, Nocozadole, and Halofuginone. 
Tissues incubated with DMEM/20% FBS averaged approximately 45% cellular PCNA 
production. Percent cells staining positive for PCNA was significantly reduced in the 
presence of all inhibitors used except Cycloheximide.
Collagen Synthesis
Serum stimulated the synthesis of Type I collagen by cells in  situ to cultured 
pericardium. Figure 15 shows tissue incubated with DMEM/20% FBS for 0 days (A) 
and 30 days (B) and stained with Masson’s Trichrome. Masson’s Trichrome, a 
collagen density stain, revealed the deposition of new collagen, which stains light blue 
(yellow arrows), in the folds of contracted tissues. In some samples, new collagen 
deposition was also observed on the surface of contracted tissues. In comparison, 
tissues harvested at day 0 stained only dark blue indicating no new collagen deposition.
Pericardial tissues were also evaluated for the synthesis of Type I procollagen. 
Tissues harvested during the process of contraction were evaluated by 
immunohistology using the sheep specific procollagen antibody SP1.D8. Figure 16 
shows cellular production of procollagen (yellow arrows) as early as day 2 after
55
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Figure 14. Chemical inhibition of cellular PCNA production. Cellular proliferation, 
evaluated by the production of proliferating cell nuclear antigen (PCNA), was 
investigated in the presence of inhibitors. Pericardial tissues (n=4) were incubated for 
4 days at 37°C, 5% C 02 with 1ml DMEM/20% FBS containing 1 p,g/ml Mitomycin C. 
Cycloheximide, Cytochalasin B, Cytochalasin D, Aphidicolin, AraC, 0.0078pg/ml 
Nocozadole, or O.lpg/ml Halofuginone. Tissues were embedded in wax, sectioned, and 
assayed by immunohistochemical techniques for the production of PCNA. Percentages 
of cells staining positive for PCNA was determined by the following formula:
(number of cells positive for PCNA / total number of cells) x 100. Error bars indicate 
standard deviation from replicate tissue samples counting 500 cells per replicate in 
random fields.
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Figure 15. Serum-stimulated collagen deposition. Pericardial tissues were incubated 
for 30 days at 37°C, 5% C02 with DMEM/20% FBS. embedded, sectioned, and stained 
with Masson’s Trichrome for collagen density. Control tissues, harvested at day 0 (A) 
showed no new collagen deposition. In contrast, tissues harvested at day 30 (B) 
showed new collagen deposition, which stained light blue (yellow arrows) in the folds 
of the original pericardium (dark blue). 400x
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Figure 16. Immunohistological staining for procollagen. Pericardial tissue sections 
were incubated with DMEM/20% FBS for 0-10 days at 37°C, 5% C 02 and evaluated 
for the cellular production of procollagen using the monoclonal antibody, SP1 .D8, 
specific for sheep procollagen. Antibody recognition was visualized by DAB staining 
resulting in a brown precipitate (yellow arrows). Tissues were counterstained with 
Hematoxylin (blue) and Eosin (pink). Procollagen production was observed as early as 
day 2 after FBS stimulation. 400x
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incubation with DMEM/20% FBS. At this time, cells staining positive for procollagen 
were randomly distributed throughout the tissue. By day 30, procollagen production 
(A) was concentrated within the folds of contracted tissues and correlated with new 
collagen deposition observed using Masson’s Trichrome staining (B) (yellow arrows) 
(Figure 17). Tissues incubated with DMEM containing 0.5% FBS for 48hrs and 
ethanol-treated tissues did not show cellular procollagen production.
Inhibition o f Collagen Synthesis
Figure 18 compares type I collagen deposition in tissues incubated with 
lOOng/ml Halofuginone (A) and DMEM/20% FBS (B) for 30 days. Masson’s 
Trichrome staining for collagen density revealed the deposition of new collagen in 
control tissue incubated with DMEM/20% FBS. An accumulation of new collagen, 
which stains light blue (yellow arrow), was observed in the folds and on the outer 
surface of the original pericardium (dark blue). In contrast, tissues incubated in 
DMEM/20% FBS containing Halofuginone stained dark blue only indicating that there 
was no new collagen deposition.
In addition, Halofuginone and Cycloheximide, but not Cytochalasin B, 
Cytochalasin D, Aphidicolin, AraC, and Nocozadole prevented serum-stimulated 
cellular procollagen synthesis. Figure 19 shows ceiiuiar procoiiagen production in 
pericardial tissues incubated with DMEM/20% FBS (A) and Halofuginone (B).
Control tissues incubated with DMEM/20% FBS showed procollagen production 
concentrated in the folds of the contracted tissues (yellow arrows). In contrast, 
procollagen synthesis was absent in tissues incubated in the presence of Halofuginone.
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Figure 17. Comparison of procollagen synthesis and collagen deposition. Pericardial 
tissues were incubated for 30 days at 37°C, 5% C 02 with DMEM/20%, embedded, 
sectioned, and evaluated for the production of collagen by immunohistological and 
histological techniques. Cellular synthesis of procollagen, evaluated using the 
monoclonal antibody, SP1.D8, specific for sheep procollagen, was observed in the 
folds of contracted tissues. Procollagen synthesis (A) correlated with new collagen 
deposition observed by Masson’s Trichrome staining for collagen density (B) (yellow 
arrows). Masson’s Trichrome stains new collagen light blue and is indicated by the 
yellow arrow. Procollagen production was visualized by DAB development resulting 
in a brown precipitate. 400x
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Figure 18. Inhibition of collagen deposition by Halofuginone. Pericardial tissues 
were incubated for 20 days at 37°C, 5% C 02 with DMEM/20% FBS containing 
lOOng/ml Halofuginone. Tissues were embedded, sectioned, and stained with 
Masson’s Trichrome for collagen density. Tissues incubated with Halofuginone (A) 
stained dark blue only indicating no new collagen production. Control tissues (B) 
showed the deposition of new collagen (light blue, yellow arrow) in the folds of the 
original collagen of the pericardium (dark blue). 400x
65
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 19. Inhibition of procollagen synthesis by Halofuginone. The cellular 
synthesis of procollagen was compared between tissues incubated with and without 
Halofuginone. Pericardial tissues were incubated for 15 days at 37°C, 5% C 02 with 
DMEM/20% FBS containing lOOng/ml Halofuginone. Procollagen synthesis, detected 
immunohistologically using the sheep specific monoclonal antibody, SP1.D8 was 
observed in control tissues (A) indicated by the yellow arrows. In contrast, tissues 
incubated in the presence of Halofuginone (B) did not show cellular procollagen 
production. Procollagen production was visualized by DAB development resulting in a 
brown precipitate. Tissues were counterstained with H&E. 400x
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Cytochalasin B, Cytochalasin D, Aphidicolin, AraC, and Nocozadole, shown 
previously to reduce serum-stimulated PCNA synthesis, did not prevent semm- 
stimulated procollagen production. Figure 20 shows procollagen production in tissues 
incubated with DMEM/20% FBS containing Cytochalasin D.
Conclusions
Tissue retraction, cellular accumulation, and matrix deposition are the three 
healing outcomes associated with the vital fibrotic flap implants in vivo. Histological 
and immunohistological analysis of these implants suggested that activation of the 
cells in situ to the implants contributed to the detrimental healing. However, this in 
vivo study was limited in the ability to identify the contribution of specific 
cardiovascular factors in relation to the observed fibrosis. For this reason, an in vitro 
model of tissue contraction was developed using living pericardium. In this model, 
serum induced tissue contraction, cellular synthesis of PCNA, and new collagen 
deposition in cultured pericardial tissue.
Serum stimulated cells in situ to cultured pericardium to contract the tissue, 
evidenced by tissue curling. Dose-dependency experiments indicated that serum- 
induced tissue contraction was related to serum concentration. DMEM containing 
20% FBS proved to be the optimal concentration of serum to induce tissue contraction 
in the shortest time frame. It is worth noting that tissues stimulated with 2% serum 
will eventually contract (approximately 14-20 days). This observation would suggest a 
threshold level of stimulation must be reached for the reaction to occur. Most tissues 
stimulated with 20% FBS contracted between 6 and 8 days. However, variability was 
observed in the length of time required for tissues to contract. This variability was not
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Figure 20. Procollagen synthesis in the presence of Cytochalasin D. Pericardial 
tissues were incubated for 4 days at 37°C. 5% C 02 with DMEM/20% FBS containing 
1 pg/ml Cytochalasin D and evaluated for the synthesis of procollagen using the sheep 
specific monoclonal antibody, SP1.D8. Cytochalasin D, which inhibited cellular 
proliferation, did not prevent procollagen synthesis (yellow arrows). Procollagen 
production was visualized by DAB development resulting in a brown precipitate. 
Tissues were counterstained with H&E. 400x
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investigated but may reflect intrinsic differences in pericardial tissue. In preliminary 
experiments, differences were observed in tissue thickness and cellular density 
between pericardium from different sheep as well as pericardial tissue sections from 
the same sheep. These differences may be related to the ability of cultured pericardium 
to respond to serum stimulation.
Serum-stimulated tissue contraction was effectively prevented by inhibitors of 
protein synthesis. Mitomycin C, an inhibitor of nucleic acid synthesis; Cycloheximide, 
an inhibitor of protein synthesis; and Halofuginone, an inhibitor of Type I collagen 
synthesis, prevented serum-stimulated tissue contraction. The ability of 
Cycloheximide to prevent tissue contraction indicated that the contraction process was 
dependent upon de novo protein synthesis, an observation reported in the inhibition of 
FPCG contraction [68]. Whereas Mitomycin C, which prevents all nucleic acid 
synthesis, also prevents protein synthesis, the ability of Halofuginone to inhibit tissue 
contraction suggested that Type I collagen production was related to tissue contraction.
Serum stimulated cells in situ to cultured pericardium to proliferate. Cellular 
proliferation was evaluated by PCNA synthesis. Cellular production of PCNA was 
variable in harvested pericardium from different sheep. For this reason, pericardium 
was serum starved for 48hrs prior to experimentation. Serum starvation was used to 
induce cells within the cultured pericardium into a quiescent state allowing for uniform 
stimulation between pericardial sections.
In a preliminary experiment, cellular PCNA synthesis (approximately 3%) was 
observed in pericardial samples incubated with serum-free DMEM for 48hr indicating 
a low stimulatory capacity of the medium. Furthermore, tissue sections stimulated
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with 2% FBS in DMEM, showed PCNA production of approximately 4% after 4 days
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synthesis of PCNA. The reason for this discrepancy may be the result of procedural 
differences. In this experiment, the rnesothelium was removed prior to serum 
stimulation, whereas in the preliminary experiment, the rnesothelium was never 
removed. Mesothelial cells are a type of endothelial cell. Endothelial cells are known 
to control the passage of nutrients to cells within the subendothelium as well as the 
activity of those cells [87]. It is therefore reasonable to consider that a lower serum 
concentration may result in a higher percent PCNA synthesis in pericardial samples 
where the rnesothelium was removed. In fact, percent PCNA production was greater in 
all pericardial samples during this experiment than during the preliminary experiment 
even when the same volumes of FBS were used in both.
In this model, percent cellular PCNA synthesis increased in a dose-dependent 
manner relative to the concentration of FBS. Concentrations of FBS greater than 50% 
were not evaluated due to the limited buffering capacity of the medium and nutritional 
requirements of the tissue. In addition, when glucose-free RPMI was used in 
replacement of DMEM, no differences were observed in percent cellular PCNA 
synthesis within tissues incubated in 50% FBS. This observation suggested that 
serum-stimulated PCNA synthesis was not completely dependent on energy 
production.
Inhibition of serum-stimulated cellular proliferation was evaluated by MTS 
metabolism on fibroblast monolayers and by cellular PCNA production in cultured 
pericardium. Formazan production from MTS metabolism was greatly reduced in the
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presence of all inhibitors. In fact, treatment with Mitomycin C, AraC, and 
Cycloheximide resulted in less formazan production than cells incubated with 0,5% 
FBS. The protein synthesis inhibitor Cycloheximide, shown to prevent tissue
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B, an inhibitor of cytoskeletal actin polymerization, showed the least inhibition of 
MTS metabolism.
Serum-stimulated PCNA synthesis was significantly reduced in the presence of 
Mitomycin C, Cytochalasin B and D, Aphidico'lin, AraC, and Halofuginone. All these 
inhibitors showed a 30% or greater reduction in cellular PCNA synthesis when 
compared to control samples. Although Cytochalasin B, Cytochalasin D, Aphidicolin, 
AraC, and Nocozadole reduced serum-stimulated PCNA production, these inhibitors 
did not prevent serum-stimulated tissue contraction. In contrast, tissue treatment with 
Cycloheximide, which prevented tissue contraction, did not reduce serum-stimulated 
PCNA synthesis.
Serum stimulated cells within cultured pericardium to synthesize and deposit 
new collagen. Masson’s Trichrome staining revealed collagen deposition in the folds 
and on the surface of pericardial tissue stimulated with 20% FBS for 30days. Parallel 
control samples, fixed at day 0, showed no new collagen staining by Trichrome. 
Furthermore, immunohistological staining showed cellular procollagen production in 
cultured pericardial tissues as early as day 2 after serum stimulation, indicating an early 
response to FBS. Tissue samples analyzed after tissue contraction showed procollagen 
production was concentrated in the folds of the tissue which correlated with Masson’s 
Trichrome staining.
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Serum-stimulated collagen synthesis was evaluated in the presence of 
Halofuginone, Cytochalasin B5 Cytochalasin D, Aphidicolin, AraC. Nocozadole, and 
Cycloheximide. Cultured pericardial tissues, which contracted in the presence of 
Cytochalasin B, Cytochalasin D, Aphidicolin, AraC, and Nocozadole, showed cellular 
production of procollagen. In contrast, pericardial tissues stimulated with 20% FBS in 
the presence of Halofuginone and Cycloheximide did not contract and the cells in situ 
to the tissue did not synthesize procollagen. These data suggested that serum- 
stimulated tissue contraction was related to the synthesis of Type I collagen.
III. Relationship Between Tissue Contraction, Cellular Proliferation, and
Collagen Deposition
The fibrotic reactions of the in vivo autologous pericardial flap implant were 
characterized by tissue contraction, cellular accumulation, and new matrix deposition. 
An in vitro model of tissue contraction was developed to study the fibrotic reactions of 
the in vivo flap in a controlled environment. In this model, cultured pericardium 
contracted, and cells within the tissue expressed the proliferative marker, PCNA, and 
synthesized Type I collagen. These reactions were analogous to the healing response 
of the in vivo pericardial flap implant and were mediated by the activation of in situ 
cells. Furthermore, cellular activation was in response to serum stimulation. In this 
chapter, we explore the relationship between serum-stimulated tissue contraction, 
proliferation, and collagen synthesis. Time dependency experiments and chemical 
inhibitors were used to evaluate the relationship between tissue contraction and 
proliferation, collagen synthesis and proliferation, and tissue contraction and collagen 
synthesis.
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Tissue Contraction and Proliferation
The interdependency of serum-stimulated tissue contraction and proliferation 
were also evaluated using chemical inhibitors. As stated previously, all inhibitors 
reduced MTS metabolism in comparison to the same number of cells stimulated with 
20% FBS (Figure 13). In addition, Mitomycin C, Cycloheximide, (Figure 7) and 
Halofuginone (Figure 8) effectively prevented serum-stimulated tissue contraction. 
Figure 21 compares formazan production by cells incubated with DMEM/20% FBS 
with and without inhibitors shown to prevent tissue contraction. In this experiment, 
Mitomycin C, Cycloheximide, and Halofuginone greatly reduced MTS metabolism to 
formazan. In contrast, Cycloheximide, which reduced formazan production, did not 
prevent serum-stimulated PCNA synthesis (Figure 22). Furthermore, concentrations 
of Cycloheximide (0.25pg/ml) that did not prevent tissue contraction still showed a 
significant reduction in MTS metabolism (not shown). Although the data relating to 
Cycloheximide appears contradictory, the question remains as to which assay more 
accurately expresses prevention of cellular proliferation. Whereas PCNA is an 
accessory protein to the DNA polymerase and therefore required for cellular 
proliferation, changes in formazan production by MTS metabolism directly represent 
cell numbers. However, data acquired during this study and by other researchers 
suggested that MTS metabolism may relate as much to the metabolism of cultured 
cells as it does to the number of cells [88]. Preliminary experimentation in this 
laboratory investigated MTS metabolism by fibroblast stimulated with increasing 
concentrations of serum. In this experiment, increases in optical density reflecting
76
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Figure 21. MTS metabolism in the presence of inhibitors that prevented tissue 
contraction. Pericardial fibroblasts (5000 cells/well, n=4) were incubated for 4 days at 
37°C, 5% C02 with DMEM/20% FBS containing Mitomycin C, Cycloheximide, or 
Halofuginone in concentrations that prevented tissue contraction. All inhibitors 
reduced formazan production when compared to control samples. Formazan 
production was evaluated by optical density recorded at 490nm. Error bars indicate the 
range of data from replicate samples.
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Figure 22. Percent cellular PCNA synthesis within cultured pericardium in the 
presence of the protein synthesis inhibitor. Cycloheximide. Pericardial tissues (n=4) 
were incubated with DMEM/20% FBS with lpg/ml Cycloheximide for 4 days at 37°C, 
5% C 02. The cellular synthesis of PCNA. was detected immunohistologically and 
visualized by DAB development resulting in a brown precipitate. Error bars indicate 
standard deviation from replicate tissue samples counting 500 cells per replicate in 
random fields.
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formazan production, were observed with increased serum concentration in fibroblast 
monolayers seeded with the same numbers of cells. Furthermore, Cytochalasin B, 
which effectively prevented PCNA production (Figure 14), did not greatly reduce MTS 
metabolism (Figure 13). It is therefore not unlikely that certain inhibitors that prevent 
PCNA production do not greatly effect the metabolism of cultured cells and in concert, 
inhibitors that reduced MTS metabolism may not effect cellular PCNA synthesis. 
Taken together, these data indicate that serum-stimulated tissue contraction and serum- 
stimulated cellular proliferation are independent events.
Collagen Synthesis and Cellular Proliferation
The interdependency of serum-stimulated collagen synthesis and serum- 
stimulated cellular proliferation were investigated by experiments involving the 
chemical inhibition of collagen synthesis and cellular proliferation. As shown earlier, 
Halofuginone, an inhibitor of Type I collagen synthesis, prevented serum-stimulated 
cellular procollagen production in tissues incubated with DMEM/20% FBS (Figure 
19). Figure 23 shows a dose-dependent reduction in MTS metabolism by fibroblast 
monolayers in the presence of Halofuginone. This reduction was not due to cell death 
since cell rounding and loss of adhesion were not observed. Figure 24 shows a 
reduction in serum-stimulated cellular PCNA production in tissue incubated in 
lOOng/ml Halofuginone when compared to tissue stimulated with DMEM/20% FBS. 
Although these data suggest serum-stimulated collagen synthesis and serum-stimulated 
cellular proliferation are linked events the mechanism by which Halofuginone prevents 
cellular proliferation is not known [89]. In contrast, the chemical inhibitors 
Cytocnaiasin B, Cytochalasin D, Aphidicolin, AraC, and Nocozadole, shown
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Figure 23. MTS metabolism in the presence of the collagen synthesis inhibitor,
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5% C 02 with DMEM/20% FBS containing serial dilutions (0.25pg/ml-0.0078pg/ml) 
of Halofuginone and assayed for the production of formazan by absorption at 490nm. 
Halofuginone (blue) reduced formazan production in a dose-dependent manner. 
Controls included fibroblasts incubated with DMEM/20% FBS (gold). Error bars 
indicate range of data from replicate samples.
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Figure 24. Percent of cells staining positive for PCNA synthesis were evaluated in the 
presence of Halofuginone. Tissues (n=4) were incubated with DMEM/20% FBS in the 
presence of lOOng/ml Halofuginone for 4 days at 37°C, 5% C 02. The production of 
PCNA was detected ininiunohistologically and visualized by DAB development 
resulting in a brown precipitate. Error bars indicate standard deviation from replicate 
tissue samples counting 500 cells per replicate in random fields.
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previously to reduce MTS metabolism by fibroblast monolayers (Figure 13) and to
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production of procollagen (Figure 20). Procollagen synthesis was also observed in 
tissue treated with Cytochalasin B, Aphidicolin, and AraC. These data confirmed that 
serum-stimulated collagen synthesis and serum-stimulated cellular proliferation were 
mutually exclusive events.
Tissue Contraction and Collagen Synthesis
The interdependency of serum-stimulated tissue contraction and cellular 
collagen synthesis were evaluated by time-related protein synthesis and by chemical 
inhibition of protein synthesis. As stated previously, serum stimulated production of 
Type I collagen by cells within cultured pericardium. In fact, procollagen 
production by randomly distributed cells was observed as early as day 2 after serum 
stimulation (Figure 16) and subsequently concentrated in the folds of contracted tissues 
by day 30 (Figure 17). Taken together with the observation that inhibition of protein 
synthesis by Cycloheximide prevented serum-stimulated tissue contraction (Figure 7), 
these data suggested that collagen production was related to tissue contraction. In 
support of this observation, Halofuginone, an inhibitor of Type I collagen synthesis, 
effectively prevented serum-stimulated tissue contraction through the experimental 
time frame of 30 days (Figure 8). In addition, collagen deposition was not seen in 
tissues stained by Masson’s Trichrome (Figure 18) and cellular procollagen production 
was not observed in tissues treated with Halofuginone (Figure 19). These observations 
suggest that serum-stimulated tissue contraction and collagen deposition are 
interdependent.
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DISCUSSION
It is not known why fibrosis occurs in some clinical cases where vital 
autologous pericardium has been used as a repair biomaterial in the cardiovascular 
system. In most cases where fresh autologous pericardium was used as a patch, 
favorable outcomes were observed. Even in cases where the tissue became fibrotic, it 
maintained its structural integrity. However, in cases where vital autologous 
pericardium was used to reconstruct heart valve leaflets, tissue retraction and fibrosis 
were the most commonly observed healing outcomes. When heart valve leaflets are 
concerned, even minimal fibrosis can have detrimental effects necessitating re­
operation and the implantation of a mechanical valve.
To better understand the differential healing responses of vital autologous 
pericardium, Cheung et al., 1999, implanted vital and ethanol-treated autologous 
pericardium as a patch, conduit, and intraluminal flap in the descending aorta of sheep 
[11]. Implants were recovered on day 5,10,15, and 30 and evaluated for cellular 
activation by histological and immunohistological techniques. Microscopically, at day 
5, both vital and ethanol-treated implants looked similar with fibrin deposits overlaying 
the pericardial implants. However, at later time points, differential healing responses 
were observed between vital and ethanol-treated implants. In ethanol-treated implants, 
there was a cessation in fibrin deposition and an orderly repopulation of the pericardial 
tissues by ceils from the aortic wall that expressed a-smooth muscle cell actin. In 
contrast, vital implants showed greater fibrin accumulation populated with randomly 
oriented cells, some of which also expressed a-actin. The origin of these cells was
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unknown but may have come from the implant, the aortic wall, or the blood stream. In 
addition, all ethanol-treated implants were covered by a surface layer of cells 
expressing von Willebrand Factor (vWF), indicative of an endothelium. The vital 
autologous patch and conduit showed some thickening and fibrosis but also eventually 
regained a vWF-expressing surface layer of cells. However, the vital autologous flap 
did not. The vital autologous flap retracted, became fibrotic, and was characterized by 
a continual deposition of clot that did not cease by termination of the experiment (30 
days). The reason for the differential healing outcomes between the vital patch and 
conduit and the vital flap are unknown but may reflect the configuration of the 
implanted tissue. Whereas the vital patch and conduit were sutured directly into the 
wall of the aorta with one surface exposed to the blood stream, the vital flap bisected 
the lumen of the aorta with both surfaces exposed to the flow of blood. In this 
configuration, the vital flap simulated a heart valve leaflet and showed healing 
characteristics similar to clinical cases where vital autologous pericardium was used to 
reconstruct or repair heart valves. Further analysis of vital and ethanol-treated 
pericardial flap implants showed different patterns in cellular activation that led to the 
detrimental healing response of the vital flap. These implants were evaluated by 
immunohistological techniques for the synthesis of proliferating cell nuclear antigen 
(PCNA) and procollagen. Like the previous in vivo study, the early time points of day 
5 and 10 showed similar patterns of cellular activation between vital and ethanol- 
treated flap implants. Cellular production of PCNA and procollagen were observed in 
the fibrin layers covering the pericardial implant as well as at the junction of the 
implants and the aortic wail. In contrast, by day 15 fibrin deposition had ceased in the
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ethanol-treated flaps that seemed to correspond with the establishment of the
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positive for PCNA and procollagen shifted from the junction of the implant and aortic 
wall to the cells that had repopulated the pericardial tissue. In vital pericardial 
implants, the opposite was observed. Concentrations of cells, staining positive for 
PCNA and procollagen in these flaps shifted from cells within the implant to cells in 
the fibrin layers covering the implants. In other words, there was a gradual shift of 
cellular activation from outside to inside the implanted tissue in ethanol-treated flaps, 
and from inside to outside the implanted tissue in vital flaps. In ethanol-treated flap 
implants, this shift in cellular activation patterns resulted in a cessation of fibrin 
deposition, reestablishment of the endothelium, repopulation of the implanted tissue, 
and an integration of the implant into the surrounding tissue. In vital flap implants, 
this shift cellular activation patterns resulted in continual fibrin deposition, a build up 
of granulation tissue, cellular accumulation, and eventual loss of the functional 
integrity of the implant. By day 30, vital implants showed cells staining positive for 
PCNA and procollagen concentrated at the interface of granulation tissue and newly 
deposited fibrin clot, which indicated a continual cycle of tissue accumulation. In this 
aspect, incomplete healing of the vital autologous pericardial flap resembled a chronic 
wound.
The above in vivo studies accentuated the healing variability of vital autologous 
pericardium used in cardiovascular surgeries, but did not indicate the mechanisms by 
which these healing responses occurred. Questions still remain as to which cells 
became activated and what signal induced the activation. In terms of the vital
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autologous pericardial flaps, the activated cells within the fibrin layers may have 
originated from the implant, the aortic wall, or from the blood stream. Although in
i
vivo models of fibrosis would best represent actual clinical situations, these studies do 
not allow for the isolation of variables responsible for the observed results.
Our approach was the development of an in vitro model of pericardial tissue 
fibrosis and contraction. The most common in vitro model of tissue contraction is 
fibroblast populated Type I collagen gels (FPCG). Although FPCGs provide useful 
information to relate tissue contraction and wound healing, these models may be too 
simplistic to adequately reflect most clinical wound healing situations. In fact, the 
FPCG model probably does not reflect cardiovascular wound healing of vital 
autologous pericardial implants. First, FPCGs are matrices composed of one type of 
tissue that is loose and unorganized. Secondly, FPCGs only contain one cell type. It is 
well known that wound healing involves the interaction of multiple cell types and that 
the extracellular matrix may regulate cell function, behavior, and morphology. Our in 
vitro model of tissue contraction was composed of living pericardial tissue with a 
complete extracellular matrix and the native cell population left intact. The only 
alteration to the tissue was the removal of the mesothelial layer. This tissue processing 
was analogous to our previous in vivo study where vital autologous pericardium was 
implanted as a flap that bisected the descending aorta of sheep. In this in vivo model, 
healing responses of the vital autologous flap resulted in retraction and fibrosis and 
was similar to clinical cases where vital autologous pericardium was used to 
reconstruct heart valve leaflets. Fibrosis of the vital autologous pericardial flap was 
characterized by tissue retraction, cellular accumulation, and matrix deposition. In
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turn, pericardial tissue reactions observed in our in vitro model were analogous to the 
observed healing responses of the in vivo vital autologous pericardial flap. Living 
pericardium cultured in our in vitro model, contracted, evidenced by tissue curling, and 
the cells within the tissue stained positive for the proliferative marker PCNA and 
deposited collagen. Therefore, our in vitro model of tissue contraction is a valid model 
of in vivo pericardial tissue healing and may reflect healing responses of vital 
autologous pericardium clinically used to repair or reconstruct heart valve leaflets.
The observation that cultured pericardial tissue in our in vitro model showed 
the similar healing characteristics as the vital autologous in vivo flap, not only 
validated our model, but also supported our primary hypothesis: cells in situ to the 
pericardial implant contributed to the detrimental healing outcome of the vital 
autologous flap.
We attempted to characterize the stimulatory component(s) within serum capable 
of inducing tissue contraction in terms of molecular weight, heat stability, and protease 
stability. We established that the stimulatory component(s) of serum was >5kDa. The 
fact that the stimulatory activity was observed in all fractions above 5kDa suggested that 
stimulatory component(s) is either a small macromolecule, which can be aggregated, a 
large macromolecule that could be broken into active fractions, or a small molecule that 
was capable of binding to a carrier protein. Interestingly, the stimulatory components) 
was partially sensitive to proteinase K treatment suggesting at least part of the active 
component was a protein, but resistant to heat denaturation up to 70°C where most 
proteins undergo conformational change.
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Using our in vitro model, we investigated serum-induced cellular activation and 
the relation of activated cells to cultured pericardial tissue contraction, cellular 
proliferation, and collagen deposition. Dose-dependency experiments and chemical 
inhibitors as well as histological and immunohistological techniques were used to 
evaluate cellular activation and subsequent pericardial tissue responses to stimulants 
found in the cardiovascular system.
In this in vitro model, cultured pericardium contracted when stimulated with 
FBS. Contraction of cultured pericardium, evidenced by tissue curling, was dose- 
dependent in response to FBS and was effective at 20% FBS. This serum-stimulated 
response was a function of cellular activation, since ethanol-treated and freeze-killed 
tissues did not contract. Furthermore, cultured pericardium stimulated with low 
concentration of FBS (0.5%) did not contract suggesting a threshold level of 
stimulation must be reached for the reaction to occur. Serum-stimulated tissue 
contraction was evaluated in the presence of Mitomycin C, Actinomycin D, 
Cytochalasin B, Cytochalasin D, Aphidicolin, AraC, Cycloheximide, Colchicine, 
Nocozadole, Prostaglandin E2, and Halofuginone. Of these compounds, Mitomycin C, 
Actinomycin D, Cycloheximide, Colchicine, and Halofuginone effectively prevented 
tissue contraction. Actinomycin D and Colchicine were later shown to be cytotoxic, 
again indicating that living cells were required for contraction to occur. Mitomycin C 
inhibits nucleic acid synthesis, which suggested that tissue contraction required cellular 
activation relating to DNA synthesis and/or gene expression. The ability of 
Cycloheximide to prevent serum-stimulated tissue contraction indicated the 
requirement de novo protein synthesis in the contraction process. This observation was
92
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
consistent with FPCG studies. However, in FPCGs, the de novo synthesized protein 
was shown to be f-actin, the actin isoform of the cytoskeleton. This observation was 
supported by inhibitor studies where treatment with Cytochalasin prevented FPCG 
contraction. In our in vitro model, neither Cytochalasin B nor Cytochalasin D 
prevented serum-stimulated pericardial tissue contraction, indicating that the 
mechanism of tissue contraction did not require f-actin polymerization. Instead, in our 
study, tissue contraction was prevented with the Type I collagen synthesis inhibitor 
Halofuginone. Therefore, one mechanism of serum-stimulated tissue contraction 
required the deposition of de novo synthesized Type I collagen.
Serum induced proliferation by cells within cultured pericardial tissues. 
Immunohistological detection of proliferating cell nuclear antigen (PCNA) indicated 
that cellular proliferation was directly proportional to the concentration of serum. 
Serum-stimulated cellular proliferation was not dependent upon glucose concentration 
since tissues maintained in glucose-free media showed similar levels of PCNA 
staining. This observation suggested that cellular proliferation was not completely 
energy dependent.
Fibroblast metabolism of MTS and cellular production of PCNA were used to 
evaluate serum-stimulated cellular proliferation in the presence of chemical inhibitors. 
MTS is a tetrazoiium salt that is metabolized in the mitochondria to the colored end- 
product formazan, which is released into the medium. Formazan production, analyzed 
by optical density, is then related to cell numbers. Fibroblasts isolated from pericardial 
tissue were stimulated with 20% FBS with and without the presence of Mitomycin C, 
Cytochalasin B, Cytochalasin D, Aphidicolin, AraC, Cycloheximide, Nocozadole, and
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Halofuginone. Mitomycin C, Cytochalasin D, Aphidicolin, AraC, Cycloheximide, and 
Halofuginone greatly reduced MTS metabolism by fibroblast monolayers stimulated 
with 20% FBS. Cytochalasin B and Nocozadole did not. These data suggested that 
most inhibitors used in this study prevented cellular proliferation, however, formazan 
production may reflect cellular metabolism to a greater extent than cell density. 
Preliminary studies involving MTS metabolism showed that formazan production by 
fibroblasts was dose-dependent upon serum concentration within consistent cell 
populations. Although the same concentration of serum (20%) was used in this 
experiment, it is possible reduction of MTS metabolism by the inhibitors may reflect 
reduction in cellular metabolism and not cell density. This theory is supported by 
differences in fibroblast metabolism of MTS in the presence of like inhibitors. For 
example, Cytochalasin B and Cytochalasin D both prevent the polymerization of f- 
actin and Cytochalasin B has an added function of blocking cellular uptake of glucose. 
However, Cytochalasin D showed a greater inhibition of formazan production than 
Cytochalasin B in the same concentration. These data suggest that Cytochalasin D may 
have an added effect on cellular metabolism of MTS.
Serum-stimulated cellular proliferation was evaluated by the cellular synthesis 
of PCNA in cultured pericardial tissues with and without the presence of inhibitors.
All inhibitors reduced cellular staining for PCNA in cultured pericardium with the 
exception of Cycloheximide. These data suggests that PCNA is not synthesized de 
novo. In relation to Cycloheximide and cellular proliferation, data acquired from MTS 
metabolism are contradictory to cellular PCNA staining. The MTS experiment 
indicated that Cycloheximide adversely affected cellular proliferation whereas the
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PCNA production data did not. It is possible that PCNA is not synthesized de novo 
whereas complete cellular division does require gene expression. If this was the case, 
then the data are accurate. However, it is also possible that Cycloheximide did not 
interfere with DNA replication, but had an added effect of altering MTS metabolism.
MTS metabolism and PCNA synthesis in the presence o f inhibitors that 
prevented tissue contraction were used to evaluate the relation between serum- 
stimulated tissue contraction and cellular proliferation. As stated above, Mitomycin C, 
Cycloheximide, and Halofuginone effectively prevented serum-stimulated tissue 
contraction. Of these inhibitors, Cycloheximide did not alter serum-stimulated cellular 
staining for PCNA in cultured pericardial tissues suggesting that serum-stimulated 
tissue contraction and cellular proliferation are independent events.
Serum-stimulated collagen deposition by cells within cultured pericardium. 
Masson’s Trichrome staining for collagen density showed collagen deposition in the 
folds of contracted pericardial tissues cultured in our in vitro model. In addition, 
immunohistological staining with the sheep specific procollagen antibody SP1.D8 
showed cellular synthesis of procollagen as early as day 2. This indicated an early 
response of cells to serum stimulation. Histological analysis of tissues harvested at 
later time points colocalized Type I procollagen synthesis with Type I collagen 
deposition observed by Masson’s Trichrome.
Serum-stimulated cellular collagen production was evaluated in the presence of 
chemical inhibitors. Tissues stimulated with 20% FBS in the presence of Cytochalasin 
B, Cytochalasin D, Aphidicolin, AraC, Nocozadole, and Halofuginone were analyzed 
for the cellular synthesis of procoiiagen. Halofuginone, which inhibited serum-
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stimulated tissue contraction, effectively prevented serum-stimulated procollagen 
synthesis. Cytochalasin B, which reduced serum-stimulated PCNA synthesis, and 
Cytochalasin D, Aphidicolin, AraC, and Nocozadole, which reduced serum-stimulated 
PCNA synthesis and serum-stimulated MTS metabolism, did not prevent tissue 
contraction or the production of Type I procollagen. These data indicated that cellular 
collagen production was not related to cellular proliferation, but was related to serum- 
stimulated tissue contraction.
Finally, we identified the molecular mass of a newly synthesized protein that 
appeared during the process of serum-stimulated pericardial tissue contraction. SDS- 
PAGE protein profiles of incubated pericardial tissues showed the appearance of at least 
one newly synthesized protein during the process of tissue contraction. This protein of 
approximately 60kDa appeared at day 4 of incubation and was absent in earlier days and 
in Cycloheximide-treated samples. The identity of this protein has not yet been 
determined.
In summary, an in vitro model of fibrosis and tissue contraction was developed. 
Pericardial tissues cultured in this in vitro model simulated healing reactions observed 
when vital autologous pericardium was implanted as flap in the descending aorta of 
sheep when stimulated by FBS. Serum stimulated cultured pericardium to contract, 
and the cells in situ to synthesis PCNA and Type I collagen. Studies involving 
chemical inhibitors indicated that serum-stimulated tissue contraction was dependent 
upon collagen deposition. The mechanism of tissue contraction through the deposition 
of collagen is unknown, but may involve the formation of substrate adhesions. In
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addition, serum-stimulated cellular proliferation was shown to be independent of both 
tissue contraction and collagen synthesis.
The data reported here indicated that fibrosis of the vital autologous pericardial 
flap occurred in response to the activation of cells in situ to the implant. These data 
also indicated that one mechanism of cellular activation was through exposure to blood 
serum, which resulted in cellular proliferation. Preliminary data involving the 
immunohistological detection of PCNA showed reduced cellular staining of PCNA 
when pericardial tissues were covered by mesothelial cells than when the mesothelium 
was completely removed. In this preliminary study, the mesothelium was restored in 
approximately 5 days after serum stimulation. In these tissues, PCNA staing was 
maximal at day 4 resulting in an average percentage of cells staining positive for 
PCNA of 12% within cultured pericardium stimulated with 10% FBS. In addition, the 
connective tissue cells synthesizing PCNA were located directly under the mesothelial 
layer. In fact, the further away from the surface, less PCNA production was observed. 
In comparison, when new techniques were employed to completely remove the 
mesothelium, average percentage of cells staining positive for PCNA was 
approximately 50% and these cells were randomly distributed throughout the tissue. 
These data suggested a regulation of connective tissue cell activation by the overlaying 
mesothelium. This was not surprising since mesothelial cells are a type of endothelial 
cell, and the endothelium is known to regulate the activity and function of cells within 
the subendothelium. Knowing the regulatory function of endothelial cells, a 
correlation may be proposed relating to healing responses of the vital and ethanol- 
treated pericardial flap implants. As stated previously, a shift in patterns of cellular
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activation and a cessation in fibrin accumulation coincided with the establishment of
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in fibrin deposition on the vital autologous patch and conduit also seemed to coincide 
with establishment of an endothelium. In contrast, fibrin deposition was continuous 
and an endothelium was never established on the vital in vivo pericardial flap. 
Therefore, it is possible that the chronic wound healing responses observed in the vital 
fibrotic flap were a consequence of the absence of an endothelium. Of course, the 
opposite may also be true that the inability of the vital flap to establish an endothelium 
may be the result of a chronic wound-healing situation.
In addition to cellular proliferation, tissue contraction and collagen deposition 
were observed in the healing responses of the in vivo vital pericardial flap and in vitro 
cultured pericardial tissue. These healing responses in vitro were the result of serum 
stimulation. Therefore, it may be assumed that one mechanism of cellular activation in 
vivo that led to tissue contraction and collagen deposition was cellular stimulation by 
blood serum. Serum-stimulated pericardial tissue contraction could be observed by 
day 4 in vitro and was evidenced by tissue curling. In comparison, retraction of the 
vital in vivo pericardial flap was not observed until day 15. Data acquired in this in 
vitro study showed an early response (day 2) of cellular activation in terms of 
procollagen synthesis when the tissue was exposed to serum. Cellular synthesis of 
Type I procollagen was also observed in the early time points (day 5) by cells within 
the in vivo vital pericardial flap. Furthermore, chemical inhibition of collagen 
synthesis in vitro alleviated serum-stimulated cultured pericardial tissue contraction 
indicating that tissue contraction and collagen deposition are linked events.
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Although this in vitro study indicated the mechanism of vital autologous 
pericardial implant fibrosis was related to activation of cells in situ to the pericardium, 
it did not reveal why these cells became activated. As stated above, cessation of fibrin 
accumulation on ethanol-treated implants and fibrotic reactions of the vital patch and 
conduit seemed to coincide with the establishment of an endothelium on the surface of 
these in vivo implants. In turn, cellular activation in relation to cellular PCNA staining 
was significantly lower in in vitro cultured pericardium where the mesothelial layer 
was intact compared to samples where the mesothelium was removed. This data 
suggested that not only was cellular activation related to serum-stimulation but cellular 
activation within pericardial implants may also be related to the removal of the 
mesothelial and subsequently the repressive factors secreted by this type of endothelial 
cell (see Endothelial cells).
In addition, pericardium is a fluid filled sack that surrounds the heart 
functioning as a cushion. It is compartmentalized in the body to the extent that 
pericardium is not exposed to blood factors or the mechanical forces generated by the 
flow of blood. Although steps were taken in vitro to counteract cellular activation due 
to mechanical stimulation, it is possible that transference of pericardium from an 
environment of low serum to an environment of high serum, aided in the activation of 
pericardial cells.
In conclusion, pericardium is an attractive biomaterial for cardiovascular repair 
surgeries. It is non-immunogenic, has excellent hemostatic qualities, and its intrinsic 
function is not needed for survival. Unfortunately, the clinical healing outcomes 
associated with the use of autologous pericardium are unpredictable and therefore limit
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its usage. Depending upon its usage, autologous pericardium was shown to become 
thin and dilated, retracted and fibrotic, or incorporated into the surrounding tissue. Our 
previous in vivo study and this in vitro study indicated that activation of cells in situ to 
pericardial tissue contributed to the detrimental healing outcomes associated with some 
vital autologous pericardial implants. In this in vitro study, we developed a model of 
pericardial tissue contraction. Within this model, we investigated the stimulatory 
characteristics of serum, the mechanism by which serum-stimulated cellular activation 
resulted in tissue contraction, cellular proliferation, and collagen synthesis, and the 
relationships between these serum-induced phenomena. We demonstrated the ability 
of serum to stimulate the activation of cells in situ to cultured pericardium resulting in 
tissue contraction, cellular proliferation, and collagen synthesis and deposition. This 
stimulatory capacity of serum was resistant to moderate heat treatment but sensitive to 
proteinase K digestion. Furthermore, the stimulatory capacity of serum could not be 
classified into a molecular weight range suggesting more than one protein or an 
interaction of two or more proteins of different masses conveyed the stimulatory 
signal. In addition, serum-stimulated pericardial tissue contraction and cellular 
proliferation were dose-dependent in relation to serum concentration and 
immunohistological staining of cellular PCNA was not dependent upon glucose 
concentration. Finally, experiments involving chemical inhibition of DNA synthesis 
and protein synthesis indicated that cellular proliferation within cultured pericardium 
was independent of both tissue contraction and collagen synthesis. However, these 
experiments showed tissue contraction was dependent upon collagen deposition.
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Overall, data acquired from this in vitro study and our previous in vivo study 
indicated that the microenvironment associated with cells and tissues is unique to those 
tissues and changes in tissue microenvironment may result in cellular activation. This 
seemingly simplistic statement has significant inferences on cardiovascular repair 
surgeries involving the use of autologous tissue. Foremost, it suggests that the source 
of the autologous tissue has dramatic effects on healing outcome and conversely, the 
healing outcome of autologous tissue transplants is influenced by the 
microenvironment in which the tissue is implanted. According to this in vitro study, 
cardiovascular surgeries involving the use of vital autologous pericardium as a repair 
biomaterial should include strategies to minimize cellular activation. These strategies 
may involve procedures designed to maintain the mesothelium, however, since the ' 
mesothelial may be removed by mere handling of the tissue, methods should be 
designed to aid in the establishment of an endothelium after pericardial tissue 
implantation. Future experiments involving the above mentioned strategies with 
studies relating to tissue treatments before implantation may alleviate the development 
of fibrosis observed with vital autologous pericardial transplants.
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